A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA

作者：Jones Simon A; Breen Catherine; Heap Fiona; Rust Stewart; de Ruijter Jessica; Tump Evelien; Marchal Jan Pieter; Pan Luying; Qiu Yongchang; Chung Jou Ku; Nair Nitin; Haslett Patrick A J; Barbier Ann J; Wijburg Frits A^*

来源：Molecular Genetics and Metabolism, 2016, 118(3): 198-205.

DOI：10.1016/j.ymgme.2016.05.006

• Enzyme replacement therapy
• Heparan sulfate
• Intrathecal drug delivery device
• Lysosomal storage disease
• Mucopolysaccharidosis IIIA (MPS IIIA)
• Sanfilippo syndrome A

Objective: This was an open-label, phase 1/2 dose-escalation, safety trial of intrathecal recombinant human heparan-N-sulfatase (rhHNS) administered via intrathecal drug delivery device (IDDD) for treating mucopolysaccharidosis IIIA (NCT01155778).
Study design: Twelve patients received 10, 45, or 90 mg of rhHNS via IDDD once monthly for a total of 6 doses. Primary endpoints included adverse events (AEs) and anti-rhHNS antibodies. Secondary endpoints included standardized neurocognitive assessments, cortical gray matter volume, and pharmacokinetic/pharmacodynamic analyses.
Results: All patients experienced treatment-emergent AEs; most of mild-to-moderate severity. Seven patients reported a total of 10 serious AEs (SAEs), all but one due to hospitalization to revise a nonfunctioning IDDD. No SAEs were considered related to rhHNS. Anti-rhHNS antibodies were detected in the serum of 6 patients and in the cerebrospinal fluid (CSF) of 2 of these. CSF heparan sulfate levels were elevated at baseline and there were sustained declines in all tested patients following the first rhHNS dose. No impact of anti-rhHNS antibodies on any pharmacodynamic or safety parameters was evident. 4 of 12 patients showed a decline in developmental quotient, 6 were stable, and 2 patients had only a single data point. No dose group showed a clearly different response pattern.
Conclusions: rhHNS administration via IDDD appeared generally safe and well tolerated. Treatment resulted in consistent declines in CSF heparan sulfate, suggesting in vivo activity in the relevant anatomical compartment. Results of this small study should be interpreted with caution. Future studies are required to assess the potential clinical benefits of rhHNS and to test improved IDDD models.

• 出版日期2016-7